Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Adaptive Biotechnologies Q2 2024 GAAP EPS $(0.31) Beats $(0.33) Estimate, Sales $43.190M Beat $38.664M Estimate

Author: Benzinga Newsdesk | August 01, 2024 04:51pm
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.33) by 6.06 percent. The company reported quarterly sales of $43.190 million which beat the analyst consensus estimate of $38.664 million by 11.71 percent. This is a 11.72 percent decrease over sales of $48.926 million the same period last year.

Posted In: ADPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist